Neurobiology of Aging
Volume 31, Issue 5 , Pages 758-764 , May 2010

Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study

  • Jasper D. Sluimer

      Affiliations

    • Alzheimer Centre and Department of Diagnostic Radiology, VU University Medical Center, Amsterdam, The Netherlands
    • Alzheimer Centre and Image Analysis Centre, VU University Medical Center, Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author at: Alzheimer Centre and Department of Diagnostic Radiology, VU University Medical Center, PO Box 7057, Boelelaan 1117, 1007 MB Amsterdam, The Netherlands. Tel.: +31 20 444 0742; fax: +31 20 444 0715.
    • ,
  • Femke H. Bouwman

      Affiliations

    • Alzheimer Centre and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Hugo Vrenken

      Affiliations

    • Alzheimer Centre and Department of Diagnostic Radiology, VU University Medical Center, Amsterdam, The Netherlands
    • Alzheimer Centre and Physics and Medical Technology, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Marinus A. Blankenstein

      Affiliations

    • Alzheimer Centre and Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Frederik Barkhof

      Affiliations

    • Alzheimer Centre and Department of Diagnostic Radiology, VU University Medical Center, Amsterdam, The Netherlands
    • Alzheimer Centre and Image Analysis Centre, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Wiesje M. van der Flier

      Affiliations

    • Alzheimer Centre and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Philip Scheltens

      Affiliations

    • Alzheimer Centre and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands

Received 3 December 2007 ,Revised 17 June 2008 ,Accepted 29 June 2008.

References 

  1. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003;10(October):605–613
  2. Bouwman FH, Schoonenboom SNM, van Der Flier WM, Van Elk EJ, Kok A, Barkhof F, et al. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol. Aging. 2007;28:1070–1074
  3. Bouwman FH, van Der Flier WM, Schoonenboom NS, Van Elk EJ, Kok A, Rijmen F, et al. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 2007. 2007;69(September (10)):1006–1011
  4. Bouwman FH, van Der Flier WM, Schoonenboom NS, Van Elk EJ, Kok A, Scheltens P, et al. Usefulness of longitudinal measurements of beta-amyloid1–42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders. Clin. Chem. 2006;52(August (8)):1604–1606
  5. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.). 1991;82(4):239–259
  6. Chan D, Fox NC, Jenkins R, Scahill RI, Crum WR, Rossor MN. Rates of global and regional cerebral atrophy in AD and frontotemporal dementia. Neurology. 2001;57(November (10)):1756–1763
  7. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol. Aging. 2006;27(March (3)):394–401(Epub August 26, 2005)
  8. Erten-Lyons D, Howieson D, Moore MM, Quinn J, Sexton G, Silbert L, et al. Brain volume loss in MCI predicts dementia. Neurology. 2006;66(January (2)):233–235
  9. Folstein MF, Folstein SE, Mchugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;12(November (3)):189–198
  10. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, et al. Effects of A beta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64:1563–1572
  11. Fox NC, Scahill RI, Crum WR, Rossor MN. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology. 1999;52(May (8)):1687–1689
  12. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al. Mild cognitive impairment. Lancet. 2006;367(April (9518)):1262–1270
  13. Hampel H, Burger K, Pruessner JC, Zinkowski R, DeBernardis J, Kerkman D, et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch. Neurol. 2005;62(May (5)):770–773
  14. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, et al. Value of CSF beta-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol. Psychiatry. 2004;9:705–710
  15. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(March (3)):228–234
  16. Hartley SW, Scher AI, Korf ESC, White LR, Launer LJ. Analysis and validation of automated skull stripping tools: a validation study based on 296 MR images from the Honolulu Asia aging study. Neuroimage. 2006;30:1179–1186
  17. Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soininen H, Pirttila T. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol. Aging. 2007;28(April (4)):507–514(Epub March 20, 2006)
  18. Jack CR, Shiung MM, Gunter JL, O’Brien PC, Weigand SD, Knopman DS, et al. Comparison of different MRI brain atrophy, rate measures with clinical disease progression in AD. Neurology. 2004;62:591–600
  19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(July (7)):939–944
  20. MRC CFAS . Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet. 2001;357(January (9251)):169–175
  21. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(December (6)):1546–1554
  22. O’Brien JT, Paling S, Barber R, Williams ED, Ballard C, McKeith IG, et al. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology. 2001;56(May (10)):1386–1388
  23. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(May (9)):1133–1142
  24. Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol. 2006;5:828–834
  25. Schonknecht P, Pantel J, Hartmann T, Werle E, Volkmann M, Essig M, et al. Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy. Psychiatry Res. 2003;120(October (3)):231–238
  26. Schoonenboom NS, van Der Flier WM, Blankenstein MA, Bouwman FH, Van Kamp GJ, Barkhof F, et al. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol. Aging. 2007;(January):
  27. Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, Murdoch G, et al. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology. 2003;61(August (4)):487–492
  28. Sluimer, J.D., van Der Flier, W.M., Karas, G., Fox, N., Scheltens, P., Barkhof, F., Vrenken, H., 2008. Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. Radiology 248 (August) 590-598. (Epub June 23, 2008).
  29. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004;23(Suppl. 1):S208–S219
  30. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage. 2002;17(September (1)):479–489
  31. van Straaten EC, Scheltens P, Knol DL, van Buchem MA, van Dijk EJ, Hofman PA, et al. Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study. Stroke. 2003;34(August (8)):1907–1912(Epub July 10, 2003)
  32. Visser PJ, Kester A, Jolles J, Verhey F. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology. 2006;67(October (7)):1201–1207
  33. Wahlund LO, Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci. Lett. 2003;339(March (2)):99–102
  34. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur. J. Neurol. 2007;14(January (1)):e1–e26
  35. Wiltfang J, Lewczuk P, Riederer P, Grunblatt E, Hock C, Scheltens P, et al. Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J. Biol. Psychiatry. 2005;6(2):69–84

PII: S0197-4580(08)00231-5

doi: 10.1016/j.neurobiolaging.2008.06.016

Neurobiology of Aging
Volume 31, Issue 5 , Pages 758-764 , May 2010

Article Tools

* Image Usage & Resolution